广州金域医学检验集团股份有限公司 关于注销已回购股份暨股份变动的公告

Core Points - The company will cancel 5,513,000 shares that were repurchased, which will reduce the total share capital from 468,771,275 shares to 463,258,275 shares [2][3][5] - The cancellation of shares is scheduled for November 18, 2024 [3][6] - The total amount spent on the repurchased shares was approximately RMB 299.96 million [5] Group 1: Share Repurchase and Cancellation - The company has conducted four share repurchase programs, acquiring a total of 5,513,000 shares, representing 1.18% of the total share capital [5] - The purpose of the repurchased shares has changed from "for equity incentives" to "for cancellation and corresponding reduction of registered capital" [5][6] - The company has completed the necessary procedures for notifying creditors regarding the share cancellation, and no objections were raised [6] Group 2: Impact of Share Cancellation - The cancellation of the repurchased shares will not affect the controlling shareholder or actual controller of the company [8] - The company's debt repayment ability and ongoing operational capacity will remain unaffected [8] - The share distribution will still meet the listing requirements, ensuring the company's listing status is not compromised [8]